Filing Flows › Bionano Genomics (BNGO) › Q1 2026 › vs Q4 2025
Bionano Genomics (BNGO) Q1 2026 vs Q4 2025 (quarter over quarter)
Bionano Genomics's revenue fell $1.3M (-16%) from $8.0M in Q4 2025 to $6.7M in Q1 2026.
Bionano Genomics, Q1 2026: revenue $6.7M (+4% year over year), operating margin -118.1%, net loss $8.3M, operating cash flow −$5.7M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $6.7M | $8.0M | −$1.3M | -16% |
| Net loss | $8.3M | $7.9M | $370K | +5% |
| Costs & expenses | $15.0M | $16.5M | −$1.5M | -9% |
| Operating costs | $14.6M | $16.5M | −$1.9M | -12% |
| Interest & other, net | $396K | −$638K | $1.0M | — |
| Income tax | $10K | $35K | −$25K | -71% |
| Cost of revenue | $3.4M | $4.6M | −$1.1M | -25% |
| Research & development | $3.1M | $3.2M | −$90K | -3% |
| SG&A | $8.0M | $8.7M | −$696K | -8% |
| Operating cash sources | $8.7M | $7.4M | $1.3M | +17% |
| Depreciation & amortization | $2.3M | $2.3M | −$27K | -1% |
| Share-based compensation | $670K | $926K | −$256K | -28% |
| Cash used in operations | $5.7M | $4.2M | $1.5M | +37% |
| Net loss absorbed | $8.3M | $7.9M | $370K | +5% |
| Working capital & other | $393K | −$495K | $888K | — |
Questions
How much did Bionano Genomics's revenue grow quarter over quarter in Q1 2026?
Bionano Genomics's revenue fell $1.3M (-16%) from $8.0M in Q4 2025 to $6.7M in Q1 2026.